Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma (RAMBO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01580969|
Recruitment Status : Active, not recruiting
First Posted : April 19, 2012
Last Update Posted : March 2, 2018
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Glioma||Drug: Bevacizumab Drug: Minocycline Radiation: Radiation||Phase 1 Phase 2|
After providing informed consent, patients will undergo screening for eligibility to participate in the study. Screening will start within 21 days prior to dosing.
Subjects will have an MRI within 21 days of starting radiation. QOL and cognition measures will be performed within 21 days of starting radiation. Radiation will be given with parameters determined on an individual basis by the radiation oncologist. Bevacizumab will be continued at 10mg/kg IV every 2 weeks. Minocycline will be given twice a day starting at 100mg PO BID. MRI, QOL, and cognitive tests will be obtained 1, 3 and 6 months after the end of radiation.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab in Patients With Recurrent gliOma (RAMBO)|
|Actual Study Start Date :||July 6, 2012|
|Actual Primary Completion Date :||January 12, 2018|
|Estimated Study Completion Date :||August 2020|
Experimental: All patients
All patients enrolled in study.
This is an open-label, multi-agent design. Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15. Blood pressure, CBC, CMP, and urine protein level, either by UA or urine protein/creatinine ratio will be checked at the beginning of each cycle.
Other Name: Avastin
Minocycline will be given by mouth twice a day starting at about half of the monotherapy maximal tolerated dose, 100 mg PO BID. Minocycline will be started on the day prior to radiation and continued until progression or intolerance. During the combined radiation, minocycline, and bevacizumab treatment, patients will be seen weekly with a CBC, CMP, and adverse event monitoring.
Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
- Rate of Adverse Events [ Time Frame: 30 months ]Rate of adverse events of minocycline and bevacizumab during reirradiation
- Response rate [ Time Frame: 30 months ]Response rate to bevacizumab, reirradiation, and minocycline
- Quality of Life [ Time Frame: 30 months ]Effects on quality of life from repeat radiation and bevacizumab
- Cognitive effects [ Time Frame: 30 months ]Effects on cognition from repeat radiation and bevacizumab
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01580969
|United States, Utah|
|Huntsman Cancer Institute|
|Salt Lake City, Utah, United States, 84112|
|Principal Investigator:||Adam Cohen, MD||University of Utah|